US IN

(888) 440-0954

OncoPeptTUME™ :
MedGenome’s Tumor Microenvironment
Analysis Solution

Neo-epitope Prioritization Analysis

Download the OncoPeptTUME whitepaper.OncoPeptTUME

Integrate OncoPeptTUME to deliver insights at various stages of the drug development pipeline:

  • A powerful genomic method to analyze the tumor microenvironment for research and diagnostic needs
  • Provides an accurate representation of the tumor microenvironment at the cellular, molecular and biochemical level
  • Requires low sample input, has a high-throughput and robust workflow, shorter analysis time and a large dataset to interrogate, all at a significantly lower price
  • Can be customized to fit cancer immunotherapy project needs and tailored to perform in preclinical and clinical settings
  • Continuously updated to include new insights from cancer immunotherapy basic and translational research

MedGenome’s OncoPeptTUME tumor microenvironment analysis solution is an NGS based RNA expression approach that offers unique insights into the tumor microenvironment beyond IHC/FACS analysis without bias from human analysis. With OncoPeptTUME, researchers have a way to analyze the tumor microenvironment of their samples at the cellular and molecular level that can complement IHC and FACS data.

MedGenome built and validated signatures using cell-type specific gene expression signatures discovered using over 4,000 expression data sets, validated on over 1,500 pure cell type expression data sets. OncoPeptTUME deeply interrogates a very large RNA-seq data set generated from a small amount of cancer tissue sample, and produces a high resolution map of the tumor microenvironment by analyzing the range of cell-types present using carefully curated cell gene expression signatures.

The tumor microenvironment is a complex heterogeneous mixture of immune and stromal cells bound together by a proteinaceous glue composed of extracellular matrix proteins.

Tumor microenvironment analysis using a genomics approach has several advantages compared with traditional IHC / FACS approaches, and can complement the current IHC / FACS approaches used by immuno-oncology researchers.

Genomics Traditional (ihc/facs-based)
Tissue type required
  • Requires less tissue material
  • FFPE/fresh frozen
  • All cell types can be analyzed from data
  • Generally limiting
  • FFPE or fresh frozen
  • Limiting cell-types can be analyzed
Data generated
  • Information content high
  • Less variability in data
  • Quantitative (relative); spatial distribution not preserved
  • Information content low
  • User to user variation high
  • Quantitative (relative); spatial distribution preserved (IHC) but not for FACS
Effort, time and cost
  • Quicker turnaround time
  • Cost effective
  • Labor and time intensive
  • Expensive per unit data generated

How Does It Work

OncoPeptTUME maps the tumor microenvironment using carefully curated gene expression signatures, which identifies each of the many cell types present within a tumor. This genomic solution approach combines RNA-sequencing data with proprietary cell-type-specific gene expression signatures to analyze the magnitude of immune permissiveness (inflammation) and the therapy-critical abundance of specific immune cells to predict the likelihood that a tumor will respond to treatment with checkpoint modulators.

Critical Insights at Specific Stages of the Cancer Immunity Cycle

MedGenome’s tumor microenvironment analysis solution provides critical assessment of the inflammatory microenvironment that modulates T-cell infiltration and its anti-tumor activities.

The OncoPeptTUME workflow uses RNA-seq data to de-convolute the structural and functional features of the tumor microenvironment

Pre-clinical clinical Post Approval
CHALLENGES
  • Discover biomarkers of patient stratification
  • Use of biomarkers for patient selection
  • Monitor durability of response
  • Analyze patient outcome
  • Predict toxicity
  • Evaluate drug resistance
OncoPeptTUME
  • High resolution mapping of gene expression in the tumor and stromal compartments
  • Accurate quantification of biomarkers before and after drug treatment
  • Gene signature expression analysis to assess changes in microenvironment
DELIVERABLES
  • List of biomarkers expressed by patients’ tumors
  • Biomarkers of patient response
  • Novel drug targets to increase efficacy and reduce toxicity

Considering genomic research?

We’re at your service

Contact MedGenome today to see how our Tumor Microenvironment Analysis can help uncover insights in your research
*
 
*
*